Compare PRAX & TTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | TTEK |
|---|---|---|
| Founded | 2015 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.5B |
| IPO Year | 2020 | 1995 |
| Metric | PRAX | TTEK |
|---|---|---|
| Price | $325.47 | $36.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $572.13 | $44.00 |
| AVG Volume (30 Days) | 364.5K | ★ 3.5M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $2,964,148,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,395.88 | $6.53 |
| P/E Ratio | ★ N/A | $91.74 |
| Revenue Growth | N/A | ★ 7.66 |
| 52 Week Low | $26.70 | $27.27 |
| 52 Week High | $354.87 | $43.14 |
| Indicator | PRAX | TTEK |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 48.78 |
| Support Level | $290.36 | $34.99 |
| Resistance Level | N/A | $38.19 |
| Average True Range (ATR) | 18.34 | 1.83 |
| MACD | -2.56 | -0.11 |
| Stochastic Oscillator | 57.24 | 47.53 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.